missing translation for 'onlineSavingsMsg'
Läs mer
Läs mer
Tocris Bioscience™ ARCC 4

Beskrivning
ARCC 4 is a potent and selective androgen receptor (AR) PROTAC™ Degrader (DC50 = 5 nM). Comprises an androgen receptor antagonist, enzalutamide, joined by a linker to a VHL E3 ligase ligand. Brings about degradation of ARs in VCaP and LNCaP prostate cancer cell lines (Dmax = 98% at 12h) in a proteasome-dependent manner, and inhibits cell proliferation. Also degrades clinically relevant AR mutants expressed in HEK293T cells. Exhibits no significant effect on glucocorticoid, estrogen or progesterone receptors at concentrations inducing AR degradation.
ARCC 4 negative control (Cat. No. 7255) also available.
PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.
Specifikationer
Specifikationer
| Kemiskt namn eller material | (2 S,4 R)-1-(-2-(2-(4-((4 '-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-[1,1 '-biphenyl]-4-yl)oxy)butoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxami |
| CAS | 1973403-00-7 |
| Kvantitet | 5 mg |
| Mål | Active Degraders |
| Molekylformel | C53H56F3N7O7S2 |
| Renhet | 0.98 |
Produkttitel
Genom att klicka på Skicka bekräftar du att du kan bli kontaktad av Fisher Scientific angående feedbacken du har lämnat i detta formulär. Vi kommer inte att dela din information för andra ändamål. All kontaktinformation som tillhandahålls ska också underhållas i enlighet med vår Sekretesspolicy.
Hittar du en möjlighet till förbättring?